Text this: A randomized, multiple-dose, multicenter, comparative parallel study to evaluate the safety and efficacy of intravenous infusion of rituximab (Hetero) and reference medicinal product (Rituximab, Roche) in Indian patients of non-hodgkin's lymphoma (HERILY)